
Stress Management: What stress does to your body and how to reduce it.
Some forms of stress are not harmful to our body such as the stress we [...]
READ MOREColorectal (CRC) cancer screening and diagnosis during the COVID-19 pandemic in Quebec, Canada
CRC is the third most common cancer in Quebec, with projected cases in 2020 consisting of 3900 in males, and 3100 in females. During the first wave of the COVID-19 pandemic which extended from March to July 2020, Quebec experienced 59 845 infections and 5829 COVID-19 -related deaths. Quebec, like all other provinces, was forced to scale back health care services including CRC screening and treatment modalities such as colonoscopy and surgery.
In January 2021, the Ministry of Health of Quebec released data related to fecal immunochemical test (FIT), colonoscopy and CRC surgery. An analysis was conducted by Dr. Mustapha Tehfe and his team of researchers and presented at the 2021 ESMO Congress to compare the 4-month period of April to July of 2020 to the same months in 2019 to study the impact of the pandemic on CRC screening and diagnosis.
Intervention | Frequency (2020 vs. 2019) |
FIT | -67.26% |
Colonoscopy | -57.8% |
Surgery | -29.5% |
Prior to the second wave in the period between August-October 2020, health care services resumed but due to the delays and back-log, FIT was still occurring 5% less than the previous year, colonoscopy 11.4% less, and CRC surgery 28% less. These data underline how the pandemic led to unprecedented delays to cancer screening, diagnosis and treatment. Though the overall impact on mortality is not yet known, it is likely to be significant. Catching up with the delays will be a major challenge and will likely require adding substantial resources to the health care system.
KRAS G12C inhibition shows potential for the improved management of advanced CRC
Patients with KRAS-mutated colorectal cancer (CRC) have a significant need for new treatment options. KRAS is part of the RAS gene family is among the most studied cancer-related genes. All human cells contain the KRAS gene which serves as an important regulator of signalling pathways that are responsible for cell proliferation, differentiation, and survival. If a mutation occurs in a KRAS gene, it may cause the cell to multiply out of control, leading to cancer.
Of the three different RAS genes – NRAS, KRAS, HRAS – KRAS is the most frequently mutated gene, occurring in 17-25% of all cancers and 30-40% of CRCs[1]. Since KRAS mutations are so common in CRC and patients with this mutation tend to experience poorer survival outcomes compared to the KRAS wild-type (the natural, unmutated form of the gene) patient population, developing KRAS-specific treatments is an area of high unmet need. To date, the development of therapies for CRC that directly target KRAS has been largely unsuccessful.
Among KRAS mutations, there exists subsets of mutations. One that is being actively studied is the KRAS G12C mutation, which represents 3-4% of CRCs.
G12C is a single point mutation in the KRAS gene, with a glycine-to-cysteine amino acid substitution at codon 12. This substitution favours the “on” or activated state of KRAS, leading to amplified signalling pathways and oncogenesis.
The KRYSTAL-1 phase I/II trial is currently evaluating the use of a targeted therapy drug, adagrasib, as both a single agent and in combination with the targeted therapy cetuximab for patients with heavily pre-treated KRAS G12C-mutated CRC. Adagrasib is a targeted agent that inhibits KRAS G12C activity by irreversibly binding to the KRAS gene and locking it in its inactive state. When a patient has the KRAS G12C mutation, it is a negative predictor for cetuximab efficacy. Therefore, the researchers hypothesized that by combining a KRAS G12C inhibitor with cetuximab, overall treatment efficacy would be improved.
In the study, patients with pre-treated KRAS-G12C-mutant CRC were randomly assigned to received either adagrasib alone or adagrasib plus cetuximab. 46 patients who had received an average of 3 previous lines of therapy received adagrasib monotherapy (single agent). Their response rate was 22% and disease control rate was 87%. Among the 23 patients who received adagrasib plus cetuximab, response rate was 39% and disease control rate of 100%.
According to lead researcher Dr. Jared Weiss, the overall response data was still too immature to determine a meaningful analysis for the duration of response (how robust are these outcomes among patients?) and progression-free survival (do these treatments extend the amount of time a patient lives with the disease, but it does not worsen?).
Adagrasib was well-tolerated with a manageable safety profile as both a single agent and in combination with cetuximab. The combination therapy is currently being evaluated as a second line therapy, in a phase III trial among patients with KRAS G12C-mutated CRC.
[1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4316144/#:~:text=Of%20the%20three%20human%20ras,survival%20and%20increased%20tumor%20aggressiveness.
Some forms of stress are not harmful to our body such as the stress we [...]
READ MOREMay 2023 Recent data presented at Digestive Disease Week in Chicago [...]
READ MOREMay 2023 A patient navigator helps patients through the healthcare [...]
READ MOREAttending a medical appointment can be daunting for some people. It is [...]
READ MOREApril 2023 A recent study published in JAMA Oncology found that amo [...]
READ MOREApril 2023 A recent study published in JAMA Network Open showed tha [...]
READ MOREMarch 2023 - Results from a phase I study presented at the American So [...]
READ MOREMarch 2023 -A German study published in BMC Cancer explored the emotio [...]
READ MOREJanuary 2023 There is increasing evidence to support the use of cir [...]
READ MOREJanuary 2023 Findings from the phase III SUNLIGHT trial were presente [...]
READ MORELocations: BC, AB, ON, QC Status: currently recruiting Trial descr [...]
READ MORENovember 2022 A new study involving patients with different cancer [...]
READ MORENovember 2022 To better understand the role of the gut microbiome i [...]
READ MOREOctober 2022 A recent study published in the Journal of the Nationa [...]
READ MOREEarlier this month, controversial news headlines emerged: “Colonoscopi [...]
READ MORELocation: Canada-wide Status: Currently recruiting Trial Descrip [...]
READ MOREFindings from the global FRESCO-2 trial showed that a drug called fruq [...]
READ MOREFindings from a study published in the Journal of Clinical Oncology de [...]
READ MOREUlcerative colitis is a chronic inflammatory bowel disease that affect [...]
READ MORECrohn’s disease is a chronic (long-term) inflammatory disease that can [...]
READ MOREIn this Q&A, Dr. Brandon Sheffield, Pathologist with the William O [...]
READ MOREIn this Q&A, Suzanne Zwicker, Clinical Pharmacist on the National [...]
READ MOREJuly 2022 The annual ESMO World Congress on Gastrointestinal (GI) C [...]
READ MOREJuly 2022 Patients who have colorectal cancer that has spread to th [...]
READ MOREJune 2022 Minimal residual disease (MRD) is a term that refers to cance [...]
READ MOREMay 2022. Image source: https://www.whathealth.com/breastcancer/her2rec [...]
READ MOREMay 2022 The KEYNOTE-177 trial is a landmark study in colorectal ca [...]
READ MOREApril 2022. A new study from Australia found that heavy drinking in [...]
READ MOREApril 2022. A study published in JAMA Network Open investigated whe [...]
READ MOREMarch 2022. While obesity is a known risk factor for colorectal can [...]
READ MOREhttps://youtu.be/-Oi2jBJDUNc February 2022. Join Patient Support Spe [...]
READ MOREJanuary 2022 Total neoadjuvant therapy (TNT) is a standard approach [...]
READ MOREJanuary 2022 Oxaliplatin is an important intravenous chemotherapy d [...]
READ MOREJanuary 2022. Laura Ferguson, a current ileostomy patient, and Karen Br [...]
READ MOREJoin Chana, our Patient Support Specialist, as she sits down to a cand [...]
READ MOREJoin Dr. Scott Berry, Professor & Department Head, Department of O [...]
READ MORELeft: Laura A. Dawson, MD, FRCPC, Princess Margaret Cancer Centre/Univ [...]
READ MOREThis month, the Food and Drug Administration (FDA) cleared an investig [...]
READ MOREIn 2016, the United States Preventive Services Task Force (U [...]
READ MOREIn 2020, Jason was diagnosed with stage 3b colorectal cancer at age 36. In [...]
READ MOREDr. Megan Bernard, naturopathic doctor, discusses a variety of tips and su [...]
READ MORENutritionist Jill Haverstock discusses a variety of tips and suggestions t [...]
READ MOREDr. Mel Borins is a family practitioner based in Toronto, Ontario. He crea [...]
READ MOREJason Abramovitch is an early age onset stage 3b colon cancer survivor who [...]
READ MOREOn December 3rd 2021, Physiotherapist Thi Tran gave a compelling session o [...]
READ MORENovember 2021 Findings from a recent study published in JAMA Networ [...]
READ MORENovember 2021 Findings from phase II of the CheckMate-142 trial sho [...]
READ MOREThe EPOCH trial is the first phase III international study evaluating the [...]
READ MOREImmunotherapy has revolutionized the way cancer is treated by boosting [...]
READ MOREA Swedish population study published this month in the Journal of the [...]
READ MOREAdjuvant (post-surgical) chemotherapy is useful in reducing the risk o [...]
READ MOREThe fecal immunochemical test (FIT) is a widely used colorectal cancer [...]
READ MORENew findings from a study presented at the European Society for Medica [...]
READ MOREWhile many different risk factors for colorectal cancer (CRC) have bee [...]
READ MOREFindings from a recent study show that multigene panel testing of patients [...]
READ MOREThe final recommendation from the United States Preventive Services Ta [...]
READ MOREPeriodontal disease (PD) is a set of inflammatory conditions that affect t [...]
READ MOREThe US Food and Drug Administration (FDA) recently approved the market [...]
READ MOREWe've posted some new recipe videos on our sister site, Foods that Fight C [...]
READ MOREThe Ontario Cancer Research Institute (OICR) held a conference on Tran [...]
READ MOREApril is Diversity Month dedicated to celebrating and honouring all in [...]
READ MOREResults from a systematic review published in JAMA Oncology found that [...]
READ MOREA study published in the Journal of Clinical Oncology Precision Oncology s [...]
READ MOREMolecular profiling in gastrointestinal (GI) cancer has been named by [...]
READ MOREYour physical, emotional and mental well-being are vital to your ability t [...]
READ MORENew findings from the University of Alberta published in the Journal of th [...]
READ MOREFindings from a recent study presented at the 2021 Gastrointestinal Ca [...]
READ MOREColorectal cancer is the second most diagnosed cancer in Canada. Twent [...]
READ MORE10 December 2020Findings from a recent study showed that people who regula [...]
READ MORE22 December 2020 Hepatic Artery Infusion (HAI) chemotherapy is sometime [...]
READ MORENovember 2020 Findings from a recent study conducted by the Mayo Clinic [...]
READ MOREThe non-surgical management or “watch-and-wait” approach for rectal c [...]
READ MOREThe incidence of colorectal cancer (CRC) is rising among young adults, who [...]
READ MOREOpportunity to Investigate the Microbiome’s Impact on Science and Treatmen [...]
READ MORENew findings from a study conducted at the University of Sheffield in [...]
READ MORESexuality and relationships during and after cancer is extremely impor [...]
READ MOREChadwick Boseman’s death from colorectal cancer (CRC) at age 43 was a shoc [...]
READ MOREToday, Wednesday September 30th, is World Metastatic Colorectal Cancer Day [...]
READ MOREDr. Heinz-Josef Lenz, MD, discusses optimal sequencing strategies for [...]
READ MOREThe European Society for Medical Oncology ESMO Virtual Congress 2020 t [...]
READ MOREJesse Fishman is a 17-year-old hockey player, currently playing for the Ki [...]
READ MORE12 August 2020 Recent findings from a Swedish cohort study found that p [...]
READ MOREIt was the day of the lockdown. My family doctor called. “The colorectal c [...]
READ MOREFill out the survey! The world was shocked late last week as we learned a [...]
READ MOREPrevious data have shown that certain species of intestinal bacteria not o [...]
READ MOREAs we transition into autumn, take a moment to appreciate the seasonal pro [...]
READ MOREThe COVID-19 pandemic has presented countless new challenges in cancer car [...]
READ MOREThe COVID-19 pandemic situation is constantly evolving. Canada is slowly r [...]
READ MOREResults of several new studies provide important perspectives on the use o [...]
READ MOREIn the past two years, findings from important clinical trials are shaping [...]
READ MOREHold the Date! On behalf of Colorectal Cancer Canada (CCC), you are cordi [...]
READ MOREWhat is Lynch Syndrome? Lynch syndrome is a genetically inherited conditi [...]
READ MORECoronavirus has taken the world by storm since the beginning of 2020, and [...]
READ MORETo ensure the health and safety of our participants, volunteers, staff and [...]
READ MOREThe American Society of Clinical Oncology (ASCO) held its annual meeting a [...]
READ MOREIn just a few months, coronavirus (COVID-19) has transformed our lives. De [...]
READ MOREIt has been known for millennia that what we eat can be powerful medicine [...]
READ MOREThe last few decades have seen important advances in colorectal cancer tre [...]
READ MORECo-leads of Push For Your Tush Ottawa share their connection to the cause [...]
READ MOREThe Centre de recherche of the Centre hospitalier universitaire de Sherbro [...]
READ MOREOn June 24, 2019, colorectal cancer screening in Ontario is changing to th [...]
READ MOREToday we remember Dr. Henry Lynch, esteemed researcher and father of hered [...]
READ MOREOn Tuesday, July 16, Colorectal Cancer Canada (CCC) held our third annual [...]
READ MOREResearchers with the World Health Organization confirm increased rates of [...]
READ MORELast Thursday and Friday, Morgan Kennedy, CCC’s Never Too Young Program Ma [...]
READ MOREColorectal Cancer Canada (CCC) is proud to announce the publication of the [...]
READ MOREToday, the Giant Colon Tour stopped at the University of Montreal Hospital [...]
READ MOREMost people do not know that cancer is the number one cause of death among [...]
READ MOREMarch is Colorectal Cancer Awareness Month! Colorectal cancer may touch yo [...]
READ MORE